However, the cerebellum was validated as a reference region for 11C-PBR28-TSPO binding in AD patients [71], but regarding differences between radiotracers’ pharmacokinetics and the variety of TSPO distribution depending on the considered disease, it is necessary to independently validate a reference region for each radiotracer and for each disease. This evidence concerns the gene TSPO and Alzheimer disease.